Senate Finance Committee leaders Friday released changes to the Prescription Drug Pricing Reduction Act that would eliminate impending Medicaid cuts to disproportionate share hospitals for two years, as advocated for by the AHA, and make permanent the Medicare payment adjustment for certain low-volume hospitals and the Medicare-Dependent Hospital Program.

The revised bill also would require states to report on non-DSH Medicaid supplemental payments; redefine Medicaid shortfall and third-party payments; require the Government Accountability Office to study and report on uncompensated care costs for disproportionate share hospitals; and increase Medicaid funding to U.S. territories for four years. In addition, the bill would extend the AHA-supported Community Mental Health Services Demonstration Program for two years and add 11 new states to the demonstration.

Among other changes, the bill would reduce beneficiary cost-sharing during the initial phase of the Part D benefit from 25% to 20% and require brand-name drugs to provide a 7% discount; reset the catastrophic discount to 14%; direct insurers to offer a cap on monthly out-of-pocket costs; and require Part D plans and pharmacy benefit managers to include concessions and fees negotiated with a pharmacy in the price beneficiaries pay at the pharmacy.    

The original bill cleared the committee in July.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The American Organization for Nursing Leadership Aug, 15 announced that Stuart Downs, DNP, R.N., was elected as the 2026 president-elect of the AONL Board of…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…